CN103919956B - 一种大肠息肉植物抑制剂的制备方法 - Google Patents
一种大肠息肉植物抑制剂的制备方法 Download PDFInfo
- Publication number
- CN103919956B CN103919956B CN201410075652.1A CN201410075652A CN103919956B CN 103919956 B CN103919956 B CN 103919956B CN 201410075652 A CN201410075652 A CN 201410075652A CN 103919956 B CN103919956 B CN 103919956B
- Authority
- CN
- China
- Prior art keywords
- colorectal polyps
- colorectal
- inhibitor
- raw material
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000022131 polyp of large intestine Diseases 0.000 title claims abstract description 59
- 239000003112 inhibitor Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 21
- 239000002994 raw material Substances 0.000 claims abstract description 52
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229960003893 phenacetin Drugs 0.000 claims abstract description 20
- 239000010018 saw palmetto extract Substances 0.000 claims abstract description 16
- 241000196324 Embryophyta Species 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 46
- 238000002390 rotary evaporation Methods 0.000 claims description 24
- 239000000287 crude extract Substances 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 240000006661 Serenoa repens Species 0.000 claims description 18
- 235000005318 Serenoa repens Nutrition 0.000 claims description 18
- 241000216674 Armillaria tabescens Species 0.000 claims description 16
- 241001411214 Cryptolepis sinensis Species 0.000 claims description 16
- 235000013311 vegetables Nutrition 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 241000334154 Isatis tinctoria Species 0.000 claims description 15
- 235000021028 berry Nutrition 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- -1 polyoxyethylene Polymers 0.000 claims description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 206010009944 Colon cancer Diseases 0.000 abstract description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 206010003694 Atrophy Diseases 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 230000037444 atrophy Effects 0.000 abstract description 3
- 241000457679 Cryptolepis sanguinolenta Species 0.000 abstract description 2
- 241000219000 Populus Species 0.000 abstract description 2
- 239000000902 placebo Substances 0.000 abstract description 2
- 229940068196 placebo Drugs 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000993291 Armillariella Species 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 29
- 241000565118 Cordylophora caspia Species 0.000 description 20
- 208000037062 Polyps Diseases 0.000 description 20
- 238000011282 treatment Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 11
- 239000000284 extract Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000002429 large intestine Anatomy 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000419 plant extract Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002599 biostatic effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 208000033309 Analgesic asthma syndrome Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000385333 Cryptolepis Species 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004736 colon carcinogenesis Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410075652.1A CN103919956B (zh) | 2014-03-03 | 2014-03-03 | 一种大肠息肉植物抑制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410075652.1A CN103919956B (zh) | 2014-03-03 | 2014-03-03 | 一种大肠息肉植物抑制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103919956A CN103919956A (zh) | 2014-07-16 |
CN103919956B true CN103919956B (zh) | 2017-01-18 |
Family
ID=51138498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410075652.1A Expired - Fee Related CN103919956B (zh) | 2014-03-03 | 2014-03-03 | 一种大肠息肉植物抑制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103919956B (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1311015A (zh) * | 2001-02-12 | 2001-09-05 | 高林 | 一种抗病毒、抗重金属、抗肿瘤的天然药物 |
CN103768314A (zh) * | 2013-12-13 | 2014-05-07 | 胡晓 | 一种治疗基孔肯雅热的中药组合物及其制备方法 |
-
2014
- 2014-03-03 CN CN201410075652.1A patent/CN103919956B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103919956A (zh) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102302555A (zh) | 一种治疗痛风性关节炎的中药提取物及其制备方法和应用 | |
CN101190280B (zh) | 梅树非果部分提取物的用途 | |
JP2011503237A (ja) | Scutellariabarbatad.donの精製抽出物を作製するためのプロセス | |
CN101584810B (zh) | 一种治疗胃炎、消化性溃疡的药物组合物及其制备方法 | |
CN104306554A (zh) | 一种治疗胃溃疡的食品、保健品或药物组合物 | |
CN103919956B (zh) | 一种大肠息肉植物抑制剂的制备方法 | |
CN104524214B (zh) | 治疗消化道溃疡的中药组合物及其中药制剂、制备方法和应用 | |
CN106214740A (zh) | 一种中药组合物及其制备方法和用途 | |
KR101556443B1 (ko) | 잣나무잎 추출물을 함유하는 항암 조성물 | |
KR20130130580A (ko) | 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 및 그 제조 방법 | |
CN111920908B (zh) | 一种治疗消化性溃疡的药物组合物 | |
WO2009135351A1 (zh) | 梅树提取物在制备组合物中的应用 | |
Stix | Spice healer | |
Rahman et al. | Integrating in vivo and in silico approaches to investigate the potential of Zingiber roseum rhizome extract against pyrexia, inflammation and pain | |
CN102949712A (zh) | 一种治疗肿瘤疾病的中西复合药物 | |
RU2646450C1 (ru) | Способ лечения предраковых и ранних стадий раковых заболеваний желудка | |
CN109010495A (zh) | 一种中药组合物及其制备方法和应用 | |
CN105853653B (zh) | 一种治疗慢性胃炎的药物组合物及其制备方法 | |
CN101152223A (zh) | 杨树叶酚类提取物在治疗心血管疾病中的用途及其提取方法 | |
CN103893512B (zh) | 一种治疗痛风性关节炎的中药组合物 | |
CN104857422B (zh) | 治疗大肠癌的组合物及用于制备治疗大肠癌药物的用途 | |
TWI826039B (zh) | 檳榔葉萃取物於治療或預防肝癌的醫藥用途 | |
KR20170079838A (ko) | 대황 및 감초 복합추출물을 함유하는 역류성 식도염 예방 또는 치료용 약학 조성물 | |
TWI693938B (zh) | 牛蒡萃取物的用途 | |
CN101926955B (zh) | 一种治疗胃病的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Kai Inventor after: Wang Shijiang Inventor before: Ye Weirong |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20161207 Address after: Huaiyin District of Ji'nan City, Shandong province 250117 Yan Ji Road, No. 440 Shandong Provincial Tumor hospital surgical ward eight Applicant after: Liu Kai Address before: Dalang District 523770 Guangdong Zhen fo Zi Ao Cun city in Dongguan province 604 Applicant before: Ye Weirong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Kai Inventor after: Wang Shijiang Inventor after: Wang Zhiqi Inventor before: Liu Kai Inventor before: Wang Shijiang |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171122 Address after: 250000 Shandong city of Ji'nan province Yan Ji Road, No. 440 Patentee after: Shandong Inst. of Tumor Prevention and Cure Address before: Huaiyin District of Ji'nan City, Shandong province 250117 Yan Ji Road, No. 440 Shandong Provincial Tumor hospital surgical ward eight Patentee before: Liu Kai |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170118 Termination date: 20180303 |
|
CF01 | Termination of patent right due to non-payment of annual fee |